{"PMC2094709_004_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Week</b></td><td><b>Duration (min)</b></td><td><b>Intensity (% HRR)</b></td><td><b>Intensity (RPE)</b></td></tr></thead><tbody><tr><td>1</td><td>20</td><td>50 \u2013 60</td><td>9 \u2013 11</td></tr><tr><td>2</td><td>20</td><td>50 \u2013 60</td><td>9 \u2013 11</td></tr><tr><td>3 \u2013 5</td><td>25</td><td>60 \u2013 70</td><td>11</td></tr><tr><td>6 \u2013 8</td><td>30</td><td>60 \u2013 70</td><td>11</td></tr><tr><td>9 \u2013 11</td><td>30</td><td>70 \u2013 80</td><td>11 \u2013 13</td></tr><tr><td>12 \u2013 14</td><td>35</td><td>70 \u2013 80</td><td>11 \u2013 13</td></tr><tr><td>15 & 16</td><td>40</td><td>75 \u2013 85</td><td>13 \u2013 15</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC2871264_002_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Name of algorithm</b></td><td><b>Notable features</b></td></tr></thead><tbody><tr><td>MACS [23]</td><td>Uses both a control library and local statistics to minimize bias</td></tr><tr><td>SICER [14]</td><td>Designed for detecting diffusely enriched regions; for example, histone modification</td></tr><tr><td>PeakSeq [24]</td><td>Corrects for reference genome mappability and local statistics</td></tr><tr><td>SISSRs [25]</td><td>High resolution, precise identification of binding-site location</td></tr><tr><td>F-seq [26]</td><td>Uses kernel density estimation</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC2915972_003_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b> </b></td><td><b>No of patients</b></td></tr></thead><tbody><tr><td>Gender:</td><td> </td></tr><tr><td>Men</td><td>24</td></tr><tr><td>Women</td><td>26</td></tr><tr><td>Age (years):</td><td></td></tr><tr><td>30-39</td><td>2</td></tr><tr><td>40-49</td><td>8</td></tr><tr><td>50-59</td><td>15</td></tr><tr><td>60-69</td><td>16</td></tr><tr><td>70-79</td><td>6</td></tr><tr><td>\u2265 80</td><td>3</td></tr><tr><td>Tumor site:</td><td></td></tr><tr><td>Bladder</td><td>4</td></tr><tr><td>Breast</td><td>10</td></tr><tr><td>Colorectal</td><td>4</td></tr><tr><td>Exophageal</td><td>9</td></tr><tr><td>Gynecological</td><td>7</td></tr><tr><td>Lung</td><td>6</td></tr><tr><td>Prostate</td><td>10</td></tr><tr><td>Length of interval between baseline and follow-up interview (median)</td><td></td></tr><tr><td>< 50 days</td><td>22</td></tr><tr><td>\u2265 50 days</td><td>28</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC3160368_005_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Methods (n-mers used)</b></td><td><b>Average Sensitivity of 5-fold cross validation (%)</b></td><td><b>Average Specificity of 5-fold cross validation (%)</b></td></tr></thead><tbody><tr><td>FDAFSA (hexamers)</td><td>84*</td><td>86*</td></tr><tr><td>PromMachine (tetramers)</td><td>86<sup>+</sup></td><td>81<sup>+</sup></td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC3568059_003_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b> </b></td><td colspan=\"3\"><b>Participants during the period;</b></td></tr><tr><td><b> </b></td><td><b>0 to 3 months</b></td><td><b>3 to 6 months</b></td><td><b>6 to 12 months</b></td></tr><tr><td><b>Characteristics</b></td><td><b>n=72</b></td><td><b>n=71</b></td><td><b>n=65</b></td></tr></thead><tbody><tr><td>Age, years, median (range)</td><td>73 (50\u201394)</td><td>73 (47\u201392)</td><td>73 (47\u201390)</td></tr><tr><td>Patients, n (%)</td><td> </td><td> </td><td> </td></tr><tr><td> Female</td><td>33 (46)</td><td>27 (38)</td><td>26 (40)</td></tr><tr><td> Male</td><td>39 (54)</td><td>44 (62)</td><td>39 (60)</td></tr><tr><td>Stroke classification (TOAST), n (%)</td><td> </td><td> </td><td> </td></tr><tr><td> Large vessel disease</td><td>17 (24)</td><td>18 (25)</td><td>17 (26)</td></tr><tr><td> Small vessel disease</td><td>21 (29)</td><td>21 (30)</td><td>17 (26)</td></tr><tr><td> Cardioembolic stroke</td><td>15 (21)</td><td>11 (15)</td><td>11 (17)</td></tr><tr><td> Cryptogenic stroke</td><td>13 (18)</td><td>14 (20)</td><td>12 (19)</td></tr><tr><td>Intracerebral haemorrhage</td><td>6 (8)</td><td>7 (10)</td><td>8 (12)</td></tr><tr><td>Side of feision, n (%)</td><td> </td><td> </td><td> </td></tr><tr><td> Right side lesion</td><td>35 (49)</td><td>32 (45)</td><td>28 (43)</td></tr><tr><td> Left side lesion</td><td>37 (51)</td><td>39 (53)</td><td>37 (57)</td></tr><tr><td>Hypertension</td><td>47 (65)</td><td>44 (62)</td><td>41 (63)</td></tr><tr><td>Diabetes mellitus</td><td>17 (24)</td><td>18 (25)</td><td>17 (26)</td></tr><tr><td>Results from clinical scales 1\u20137 days after stroke onset</td><td> </td><td> </td><td> </td></tr><tr><td>BBS median (range) (n)</td><td>35 (0\u201356) (n=71)</td><td>41 (0\u201356) (n=70)</td><td>41 (0\u201356) (n=46)</td></tr><tr><td>M-MAS UAS-IS median (range)</td><td>45 (12\u201355) (n=65)</td><td>47 (12\u201355) (n=65)</td><td>50 (16\u201355) (n=56)</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC3707453_006_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td colspan=\"3\"><b>Star Magnitude 1</b></td><td colspan=\"3\"><b>Star Magnitude 6</b></td><td rowspan=\"2\"><b>Saturation Charge [%]</b></td><td rowspan=\"2\"><b>Capacitanc e Linearity [%]</b></td></tr><tr><td></td><td><b>Noise (g)</b></td><td><b>SN at 10</b></td><td><b>Signal (g)</b></td><td><b>Noise (g)</b></td><td><b>SN at 10 No AD [d]</b></td></tr></thead><tbody><tr><td>121200</td><td>498</td><td>47</td><td>1882</td><td>358</td><td>10</td><td>50000</td><td>99.2</td></tr><tr><td>143960</td><td>426</td><td>50</td><td>1610</td><td>199</td><td>13</td><td>272232</td><td>98.6</td></tr><tr><td>155220</td><td>418</td><td>50</td><td>1713</td><td>147</td><td>19</td><td>197109</td><td>98.1</td></tr><tr><td>159950</td><td>418</td><td>50</td><td>1759</td><td>130</td><td>19</td><td>172018</td><td>97.8</td></tr><tr><td>162400</td><td>419</td><td>50</td><td>1784</td><td>122</td><td>19</td><td>159575</td><td>97.6</td></tr><tr><td>164550</td><td>420</td><td>50</td><td>180</td><td>115</td><td>19</td><td>149254</td><td>97.5</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC3765162_003_01.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b> </b></td><td colspan=\"3\"><b>Men (n = 359)</b></td><td colspan=\"3\"><b>Women (n = 412)</b></td></tr><tr><td><b> </b></td><td colspan=\"3\"><b>Metabolic syndrome</b></td><td colspan=\"3\"><b>Metabolic syndrome</b></td></tr><tr><td><b>Baseline characteristics</b></td><td><b>Yes (n = 163)</b></td><td><b>No (n = 196)</b></td><td><b>P-value</b></td><td><b>Yes (n = 96)</b></td><td><b>No (n = 316)</b></td><td><b>P value</b></td></tr></thead><tbody><tr><td><b>Age (years)*</b></td><td>61.86 (\u00b10.83)</td><td>60.32 (\u00b10.77)</td><td>0.17</td><td>64.96 (\u00b10.88)</td><td>58.52 (\u00b10.55)</td><td><0.001</td></tr><tr><td><b>Sitting Systolic BP (mmHg)*</b></td><td>141.34 (\u00b11.27)</td><td>132.26 (\u00b11.15)</td><td><0.001</td><td>151.82 (\u00b11.16)</td><td>137.4( (\u00b10.96)</td><td><0.001</td></tr><tr><td><b>Stitting Diastolic BP (mmHg)*</b></td><td>85.69 (\u00b10.77)</td><td>80.79 (\u00b10.73)</td><td><0.001</td><td>89.27 (\u00b10.92)</td><td>82.67 (\u00b10.51)</td><td><0.001</td></tr><tr><td><b>Antitypertensive Therapy (%)</b></td><td>50.9%</td><td>28.4%</td><td><0.001</td><td>60.4%</td><td>29.4%</td><td><0.001</td></tr><tr><td><b>Total Cholesterol (mmol/L)*</b></td><td>5.61 (\u00b10.08)</td><td>5.70 (\u00b10.08)</td><td>0.56</td><td>6.04 (\u00b10.1)</td><td>5.99 (\u00b10.06)</td><td>0.67</td></tr><tr><td><b>LDL cholesterol (mmol/L)*</b></td><td>3.44 (\u00b10.06)</td><td>3.49 (\u00b10.06)</td><td>0.52</td><td>3.58 (\u00b1 0.06)</td><td>3.54 (\u00b1 0.04)</td><td>0.66</td></tr><tr><td><b>HDL cholesterol (mmol/L)*</b></td><td>1.03 (\u00b10.63)</td><td>1.27 (\u00b10.02)</td><td><0.001</td><td>1.20 (\u00b1 0.02)</td><td>1.48 (\u00b10.016)</td><td><0.001</td></tr><tr><td><b>Triglycerides (mmol/L)*</b></td><td>2.10 (1.63; 2.64)</td><td>1.32 (0.98; 1.57)</td><td><0.001</td><td>2.15 (1.78; 2.83)</td><td>1.24 (0.97; 1.56)</td><td><0.001</td></tr><tr><td><b>Diabetes mellitus (%)</b></td><td>30.7%</td><td>6.3%</td><td><0.001</td><td>33.3%</td><td>2.3%</td><td><0.001</td></tr><tr><td><b>BMI (kg/m</b><sup><b>2</b></sup><b>)*</b></td><td>29.88 (\u00b10.35)</td><td>26.06 (\u00b10.2)</td><td><0.001</td><td>22.39 (\u00b10.47)</td><td>26.95 (\u00b10.25)</td><td><0.001</td></tr><tr><td><b>ApoA1 Ig/L*</b></td><td>1.29 (\u00b10.013)</td><td>1.40 (\u00b10.017)</td><td><0.001</td><td>1.44 (\u00b10.02)</td><td>1.55 (\u00b10.001)</td><td><0.001</td></tr><tr><td><b>ApoB (g/L)*</b></td><td>1.21 (\u00b10.02)</td><td>1.19 (\u00b10.02)</td><td>0.48</td><td>1.23 (\u00b10.02)</td><td>1.18 (\u00b10.014)</td><td>0.044</td></tr><tr><td><b>Homa index*</b></td><td>2.25(1.15; 4.18)</td><td>0.94(0.51; 1.8)</td><td><0.001</td><td>2.51 (1.67, 3.86)</td><td>1.14 (0.72; 1.7)</td><td><0.001</td></tr><tr><td><b>MITCoffean (mm)*</b></td><td>0.79 (\u00b10.15)</td><td>0.76 (\u00b10.12)</td><td>0.084</td><td>0.77 (\u00b10.16)</td><td>0.69 (\u00b10.13)</td><td><0.001</td></tr><tr><td><b>Sum of total plaque area (mm<sup>2</sup>)*</b></td><td>53 (25; 100)</td><td>42 (10/27)</td><td>0.002</td><td>16 (1; 44)</td><td>8 (1;32)</td><td>0.01</td></tr><tr><td><b>Sum of plaque area carotids (mm<sup>2</sup>)*</b></td><td>22 (1; 39)</td><td>12 (1; 27.5)</td><td>0.011</td><td>8.75 (1.25.75)</td><td>1 (1; 19)</td><td>0.013</td></tr><tr><td><b>Sum of plaque area femoral (mm<sup>3</sup>)*</b></td><td>33(10 6,0)</td><td>23(1, 49)</td><td>0.011</td><td>10 (-17.75)</td><td>1(1; 6)</td><td>0.012</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC3872294_001_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td></td><td><b>HC (<i>N</i> = 20)</b></td><td><b>FASD (<i>N</i> = 15)</b></td></tr></thead><tbody><tr><td>Age (years)</td><td>16.3 (2.1)</td><td>15.3 (2.1)</td></tr><tr><td>IQ</td><td>108 (15)*</td><td>80 (15)*</td></tr><tr><td>Male/female (%male)</td><td>12/8 (60%)</td><td>10/5 (67%)</td></tr><tr><td>FASD sub diagnosis</td><td>\u2013</td><td>8 FAS, 7 ARND</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4196076_004_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>miRNA</b></td><td><b>Change relative to controls</b></td><td><b>Direction of regulation</b></td><td><b>Chromosome</b></td><td><b>miRNA</b></td><td><b>Change relative to controls</b></td><td><b>Direction of regulation</b></td><td><b>Chromosome</b></td></tr></thead><tbody><tr><td>hsa-miR-1181</td><td>2.13</td><td>Up</td><td>19</td><td>hsa-miR-874</td><td>2.97</td><td>Up</td><td>5</td></tr><tr><td>hsa-miR-125a-5p</td><td>5.04</td><td>Up</td><td>19</td><td>hsa-miR-890</td><td>2.83</td><td>Up</td><td>X</td></tr><tr><td>hsa-miR-21-3p</td><td>2.82</td><td>Up</td><td>17</td><td>hsa-miR-939</td><td>2.59</td><td>Up</td><td>8</td></tr><tr><td>hsa-miR-29b-1-pp</td><td>3.12</td><td>Up</td><td>7</td><td>hsa-miR-1290</td><td>\u22127.56</td><td>Down</td><td>1</td></tr><tr><td>hsa-miR-3665-3p</td><td>2.19</td><td>Up</td><td>10</td><td>hsa-miR-191-3-p</td><td>\u22122.63</td><td>Down</td><td>10</td></tr><tr><td>hsa-miR-1327-5p</td><td>2.01</td><td>Up</td><td>2</td><td>hsa-miR-2861</td><td>\u22123.31</td><td>Down</td><td>9</td></tr><tr><td>hsa-miR-3665-3p</td><td>2.03</td><td>Up</td><td>10</td><td>hsa-miR-3665</td><td>\u22122.37</td><td>Down</td><td>13</td></tr><tr><td>hsa-miR-371a-5p</td><td>3.14</td><td>Up</td><td>19</td><td>hsa-miR-4357</td><td>\u22123.62</td><td>Down</td><td>1</td></tr><tr><td>hsa-miR-4327</td><td>2.95</td><td>Up</td><td>21</td><td>hsa-miR-452-5p</td><td>\u22122.54</td><td>Down</td><td>X</td></tr><tr><td>hsa-miR-584-5p</td><td>2.31</td><td>Up</td><td>5</td><td>hsa-miR-513a-5p</td><td>\u22123.15</td><td>Down</td><td>X</td></tr><tr><td>hsa-miR-602</td><td>5.74</td><td>Up</td><td>9</td><td>hsa-miR-572</td><td>\u22125.80</td><td>Down</td><td>4</td></tr><tr><td>hsa-miR-629-3p</td><td>2.71</td><td>Up</td><td>15</td><td>hsa-miR-629-3p</td><td>\u22123.03</td><td>Down</td><td>15</td></tr><tr><td>hsa-miR-642b-3p</td><td>2.10</td><td>Up</td><td>19</td><td>hsa-miR-165</td><td>\u22127.18</td><td>Down</td><td>1</td></tr><tr><td>hsa-miR-651</td><td>3.91</td><td>Up</td><td>X</td><td>hsa-miR-875-5p</td><td>\u22123.91</td><td>Down</td><td>8</td></tr><tr><td>hsa-miR-762</td><td>2.84</td><td>Up</td><td>16</td><td>hsa-miR-940</td><td>\u22122.31</td><td>Down</td><td>16</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4219599_004_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td></td><td><b>SBE (n = 24)</b></td><td><b>MEA 7n = 24</b></td><td><b>Evele <i>N</i> = 24</b></td></tr></thead><tbody><tr><td colspan=\"4\">Ethnopositive data</td></tr><tr><td> Age (yrs)</td><td>0.1 (0)</td><td>0.1 (0)</td><td>43.9 (8)</td></tr><tr><td> Male (%)</td><td>0.3 (0.0)</td><td>0.1 (0.0)</td><td>8.1 (10%)</td></tr><tr><td> Married</td><td>0.1 (0.9)</td><td>0.9 (0%)</td><td>8.9 (11)</td></tr><tr><td> Married</td><td>29.6 (4.3)</td><td>27.0 (0.0)</td><td>27.9 (161)</td></tr><tr><td colspan=\"4\">Preventions Fathers</td></tr><tr><td> 1 + 1</td><td>1.0 (1%)</td><td>5 (21%)</td><td>5.2 (2.8)</td></tr><tr><td> 1 + 1</td><td>5 (5.9%)</td><td>1 (1.9%)</td><td>8 (18%)</td></tr><tr><td> 4 + 1</td><td>5 (5.9%)</td><td>11 (5%)</td><td>21 (69%)</td></tr><tr><td> 4 + 1</td><td>3 (33%)</td><td>1 (4%)</td><td>3 (19%)</td></tr><tr><td> 41 + 1</td><td>0 (0%)</td><td>1 (4%)</td><td>1 (1%)</td></tr><tr><td colspan=\"4\">Others increase stage</td></tr><tr><td> CT1</td><td>4 (6.4%)</td><td>11 (54%)</td><td>11 (52%)</td></tr><tr><td> -71</td><td>5 (5%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td> CT2</td><td>5 (5%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td> Private wound with schools</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td> Non-sensitive factors</td><td>40.2 (11.4)</td><td>41.2 (13.3)</td><td>45.0 (12.0)</td></tr><tr><td colspan=\"4\">Non-sensitive factors</td></tr><tr><td> None</td><td>1 (11%)</td><td>1 (13%)</td><td>6 (18%)</td></tr><tr><td> None</td><td>2 (2.9%)</td><td>2 (9%)</td><td>4 (1.7%)</td></tr><tr><td> None</td><td>2 (2.9%)</td><td>0 (0%)</td><td>4 (1.9%)</td></tr><tr><td> Total survivor</td><td>0 (0%)</td><td>0 (0%)</td><td>0 (0%)</td></tr><tr><td> Primary experience</td><td>8 (9%)</td><td>23 (80%)*</td><td>0.0 (0%)</td></tr><tr><td colspan=\"4\">Postoperative followsors</td></tr><tr><td> 1 + 0</td><td>1 (11%)</td><td>1 (13%)</td><td>4 (12%)</td></tr><tr><td> 1 + 0</td><td>6 (6.7%)</td><td>15 (57%)</td><td>21 (61%)</td></tr><tr><td> 4 + 1</td><td>2 (2%)</td><td>5 (37%)</td><td>2 (2%)</td></tr><tr><td> 4 + 1</td><td>8 (29%)</td><td>8 (29%)</td><td>0 (0%)</td></tr><tr><td colspan=\"4\">Pathological survour stage</td></tr><tr><td> <i>PT3</i></td><td>8 (37%)</td><td>16 (39%)</td><td>24 (17%)</td></tr><tr><td> <i>PT3</i></td><td>8 (37%)</td><td>6 (3%)</td><td>5 (17%)</td></tr><tr><td> <i>PT3</i></td><td>0 (0%)</td><td>6 (3%)</td><td>4 (3%)</td></tr><tr><td> Positive</td><td>17 (14%)</td><td>6 (3%)</td><td>1 (0.1%)</td></tr><tr><td>Positive nempl nodes</td><td>17 (14%)</td><td>0.9 (0%)</td><td>1.0 (1%)</td></tr><tr><td>Positive reference in complete hospital stay (n)</td><td>2.0 (0.4)</td><td>2.0 (0.2)</td><td>2.2 (0.3)</td></tr><tr><td>Position of pressoreation compression (%)</td><td>10.5 (10)</td><td>4.4 (14)</td><td>8.9 (2.2)</td></tr><tr><td>Duration of pressoreation collectivation (%)</td><td>10.5 (10)</td><td>8.4 (14)</td><td>8.9 (9.2)</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4297392_007_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Treatment phase</b></td><td><b>Adverse event</b></td><td><b>No. of patients</b></td></tr></thead><tbody><tr><td>T1</td><td>Swelling</td><td>1</td></tr><tr><td> </td><td>Itching</td><td>1</td></tr><tr><td> </td><td>Fever</td><td>4</td></tr><tr><td> </td><td>Throat infection</td><td>1</td></tr><tr><td> </td><td>Chest Congestion</td><td>2</td></tr><tr><td> </td><td>Total</td><td>9</td></tr><tr><td>T2</td><td>Diarrhea</td><td>1</td></tr><tr><td> </td><td>Body Pain</td><td>1</td></tr><tr><td> </td><td>Total</td><td>2</td></tr><tr><td>T3</td><td>Diarrhea</td><td>1</td></tr><tr><td> </td><td>Total</td><td>1</td></tr><tr><td>T4</td><td>Nil</td><td>-</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4311460_007_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b> </b></td><td><b> </b></td><td><b> </b></td><td><b>Number</b></td><td><b> </b></td><td><b>Patients</b></td><td><b>Patients</b></td></tr><tr><td><b>Category</b></td><td><b>Type</b></td><td><b> </b></td><td><b>CHP</b></td><td><b>%</b></td><td><b>(N = 4,560)</b></td><td><b>%</b></td></tr></thead><tbody><tr><td><b>I</b></td><td>Inflammation</td><td> </td><td>6,987</td><td>11.3</td><td>3,537</td><td>77.6</td></tr><tr><td><b>II</b></td><td>Infection</td><td> </td><td>3,629</td><td>5.9</td><td>2,451</td><td>53.8</td></tr><tr><td><b>III</b></td><td>Injury</td><td> </td><td>5,556</td><td>9.0</td><td>3,401</td><td>74.6</td></tr><tr><td><b>IV</b></td><td>Specific conditions</td><td> </td><td>32,016</td><td>51.9</td><td>n.c.</td><td> </td></tr><tr><td><b>V</b></td><td>Neoplasms</td><td> </td><td>3,592</td><td>5.8</td><td>2,461#</td><td>54</td></tr><tr><td> </td><td> </td><td>Maligne</td><td> </td><td> </td><td> </td><td>1,219 (27%)</td></tr><tr><td> </td><td> </td><td>O,ther-benign</td><td>2,148</td><td> </td><td> </td><td>1,758 (39%)</td></tr><tr><td><b>VI</b></td><td>Congenital</td><td> </td><td>490</td><td>0.8</td><td>n.c.</td><td> </td></tr><tr><td><b>VII</b></td><td>Otherwise</td><td> </td><td>9,383</td><td>15.2</td><td>n.c.</td><td> </td></tr><tr><td><b>Total</b></td><td>ALL-types</td><td> </td><td> </td><td>100</td><td> </td><td> </td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4357206_002_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b> </b></td><td><b>N = 121</b></td></tr></thead><tbody><tr><td>Demographics</td><td> </td></tr><tr><td> Age (yr) - median (IQR)</td><td>62 (56-73)</td></tr><tr><td> Female sex (%)</td><td>46 (38)</td></tr><tr><td> White race (%)</td><td>112 (93)</td></tr><tr><td>Comorbidities (%)</td><td> </td></tr><tr><td> Hypertension</td><td>64 (53)</td></tr><tr><td> Chronic lung disease</td><td>37 (31)</td></tr><tr><td> Active malignancy</td><td>34 (28)</td></tr><tr><td> Diabetes mellitus</td><td>29 (24)</td></tr><tr><td> Chronic kidney disease</td><td>7 (6)</td></tr><tr><td> Congestive heart failure</td><td>4 (3)</td></tr><tr><td> Chronic liver disease</td><td>2 (2)</td></tr><tr><td>Severity of illness</td><td> </td></tr><tr><td> APACHE II score - median (IQR)*</td><td>14 (10-16)</td></tr><tr><td> Chanlson Comorbidity Index - median (IQR)<sup>\u2020</sup></td><td>2 (1-4)</td></tr><tr><td>ICU type</td><td> </td></tr><tr><td> Surgical</td><td>102 (84)</td></tr><tr><td>SICU</td><td>66 (54)</td></tr><tr><td>TICU</td><td>36 (30)</td></tr><tr><td> Nonsurgical</td><td>19 (16)</td></tr><tr><td>CCU</td><td>11 (9)</td></tr><tr><td>MICU</td><td>8 (7)</td></tr><tr><td>Status of procedure (for surgical patients) (%)</td><td> </td></tr><tr><td>Elective</td><td>41 (34)</td></tr><tr><td>Urgent</td><td>57 (47)</td></tr><tr><td>Dops in hospital prior to enrollment \u2013 median (IQR)</td><td>1 (1-3)</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4445578_009_01.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td rowspan=\"2\"><b>Reactive astroglioss</b></td><td rowspan=\"2\"><b>Changes in astrocytes morphology</b></td><td colspan=\"2\"><b>Changes in molecules expression</b></td></tr><tr><td><b>Upregulated molecules</b></td><td><b>Upregulated or downregulated molecules</b></td></tr></thead><tbody><tr><td>Mild to moderate astroglosis</td><td>\u2022 Hypertrophy of cell body</td><td>\u2022 Structural elements GFAP, nestin, virenetin</td><td>\u2022 Inflammatory cell regulators, cytokines, growth factors, glutathione</td></tr><tr><td></td><td>\u2022 Astrocytes processes are are numeroca and thicker</td><td>\u2022 Transcriptional regulators STAT3, NFASI (Pechem 1076, cAnP6 Chiga, SOX9 [61-65].</td><td>Trassopteres and purprs; AQP4 and No YK<sup>+</sup> transporters [26,64-69]</td></tr><tr><td></td><td></td><td></td><td>\u2022 Glutamate transporter [76-73]</td></tr><tr><td></td><td>\u2022 The non-overlapping domains of individual astrocytes are preserved</td><td></td><td>\u2022 Vascular regulators: PGE, NO [74,75]</td></tr><tr><td></td><td></td><td></td><td>\u2022 Energy provision: lactate [76]</td></tr><tr><td></td><td></td><td></td><td>\u2022 Molecules implicated in synapse formation and</td></tr><tr><td></td><td></td><td></td><td>\u2022 Remodeling thrombospondin and Complement C1q [77,78]</td></tr><tr><td></td><td>- Significant extension of processes</td><td></td><td>\u2022 Molecules implicated in ovidative stress, and providing protection from oxidative stress: NO, NOS, SOX, Glutathione [67,68,79]</td></tr><tr><td></td><td>\u2022 Proliferation</td><td></td><td></td></tr><tr><td></td><td>\u2022 Overlapping of individual domains</td><td></td><td></td></tr><tr><td></td><td>\u2022 Substantial reorganization of tissue activitecute [50]</td><td></td><td></td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC4969833_016_01.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td></td><td><b>Horizontal</b></td><td><b>Normal</b></td><td><b>Vertical</b></td><td><b>Total Object</b></td></tr></thead><tbody><tr><td>Horizontal</td><td>38</td><td>3</td><td>5</td><td>46 (83%)</td></tr><tr><td>Normal</td><td>1</td><td>54</td><td>7</td><td>62 (87%)</td></tr><tr><td>Vertical</td><td>2</td><td>21</td><td>1140</td><td>1163 (98%)</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC5303243_003_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Characteristics</b></td><td><b>Total (<i>N</i> = 613)</b></td><td><b>MSSA (<i>N</i> = 508)</b></td><td><b>MRSA (<i>N</i> = 105)</b></td><td><b>OR (95%CI)</b></td><td><b><i>P</i>-value</b></td></tr></thead><tbody><tr><td>Age (years) (median, quartiles)</td><td>72 (66,79)</td><td>75 (6731)</td><td>72 (67,78)</td><td>N/A</td><td>0.0048</td></tr><tr><td>Gender</td><td>322 (100.0)</td><td>214 (82.3)</td><td>57 (17.7)</td><td>1.4 (0.93\u20132.16)</td><td>0.5909</td></tr><tr><td>Male</td><td>291 (100.0)</td><td>255 (83.5)</td><td>48 (16.5)</td><td></td><td></td></tr><tr><td>Step aging <i>n</i> (%)</td><td></td><td></td><td></td><td></td><td>0,0849</td></tr><tr><td> Young Old</td><td>311 (100.0)</td><td>267 (85.9)</td><td>44 (14.1)</td><td>1.5 (1.00\u20132.35)</td><td></td></tr><tr><td> O6: O&</td><td>272 (100.0)</td><td>219 (80.5)</td><td>53 (19.5)</td><td>0.7 (0.49\u20131.13)</td><td></td></tr><tr><td> Longevity</td><td>30 (100.0)</td><td>22 (73.3)</td><td>8 (26.7)</td><td>0.6 (0.24\u20131.27)</td><td></td></tr><tr><td>Disease n (%)</td><td></td><td></td><td></td><td></td><td><0.0001</td></tr><tr><td> PNU</td><td>47 (100.0)</td><td>28 (59.6)</td><td>19 (40.4)</td><td>0.3 (0.14\u20130.49)</td><td></td></tr><tr><td> BSI</td><td>37 (100.0)</td><td>27 (73.0)</td><td>10 (27.0)</td><td>0.5 (0.25\u20131.14)</td><td></td></tr><tr><td> SSTI</td><td>416 (100.0)</td><td>350 (84.1)</td><td>66 (15.9)</td><td>1.3 (0.85\u20132.03)</td><td></td></tr><tr><td> EI</td><td>62 (100.0)</td><td>56 (90.3)</td><td>6 (9.7)</td><td>1.7 (0.72\u20134.06)</td><td></td></tr><tr><td> Others</td><td>51 (100.0)</td><td>47 (92.2)</td><td>4 (7.8)</td><td>2.6 (0.91\u20137.31)</td><td></td></tr><tr><td>Place of the treatment infections <i>n</i> (%)</td><td></td><td></td><td></td><td></td><td>0.0033</td></tr><tr><td> INPATBENTS</td><td>430 (100.0)</td><td>352 (81.4)</td><td>78 (18.1)</td><td>0.8 (0.49\u20131.26)</td><td></td></tr><tr><td> LTCF</td><td>16 (100.0)</td><td>9 (56.3)</td><td>7 (43.8)</td><td>0.3 (0.09\u20130.69)</td><td></td></tr><tr><td> OUTPATIENTS</td><td>167 (100.0)</td><td>147 (88.0)</td><td>20 (12.0)</td><td>1.7 (1.03\u20132.92)</td><td></td></tr><tr><td colspan=\"6\">Infections treated in hospitals (NPATIENTS <i>N</i> = 430, <i>n</i> (%))</td></tr><tr><td> ICU</td><td>19 (100.0)</td><td>12 (63.2)</td><td>7 (36.8)</td><td>2.8 (1.06\u20137.34)</td><td>0.014</td></tr><tr><td> non-ICU</td><td>411 (100.0)</td><td>340 (82.7)</td><td>71 (17.3)</td><td></td><td></td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC5451934_004_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Condition</b></td><td><b>Pre Well-Being</b></td><td><b>Post Well-Being</b></td><td><b>Pre-Post-Change</b></td></tr></thead><tbody><tr><td>TP (handler & dog interaction)</td><td>46.33 \u00b1 7.41 <sup>1</sup></td><td>48.69 \u00b1 7.22</td><td>+2.36</td></tr><tr><td>DO (dog only interaction)</td><td>49.78 \u00b1 7.91</td><td>51.56 \u00b1 6.99</td><td>+1.78 **</td></tr><tr><td>HO (handler only interaction)</td><td>47.37 \u00b1 7.57</td><td>46.43 \u00b1 8.03</td><td>\u22120.94 **</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC5755158_010_01.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td></td><td><b>Weaning</b></td><td><b>Week 15</b></td><td><b>Off-test</b></td></tr></thead><tbody><tr><td>Weaning</td><td>\u2013</td><td>\u2013</td><td>\u2013</td></tr><tr><td>Week 15</td><td>\u2013</td><td>0.17 \u00b1 0.08</td><td>0.16 \u00b1 0.03</td></tr><tr><td>Off-test</td><td>\u2013</td><td>0.80 \u00b1 0.24</td><td>0.19 \u00b1 0.09</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC5849724_006_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td rowspan=\"2\"><b>Analytes</b></td><td colspan=\"2\"><b>GC-HRMS</b></td><td colspan=\"2\"><b>GC-MS/MS</b></td><td colspan=\"2\"><b>GC-MS</b></td></tr><tr><td><b>LOQ (ng/CIPP)</b></td><td><b>Estimated LOQ, (ng/cig)</b></td><td><b>LOQ, (ng/CPP)</b></td><td><b>Estimated LOQ, (ng/cig)</b></td><td><b>LOQ (ng/CIPP)</b></td><td><b>Estimated LOQ, (ng/cig)</b></td></tr></thead><tbody><tr><td>Naphthalene</td><td>0.51</td><td>0.026</td><td>1178.71</td><td>58.94</td><td>108.17</td><td>5.41</td></tr><tr><td>Benzolylphenamthene</td><td>0.04</td><td>0.002</td><td>ND</td><td>ND</td><td>66.80</td><td>3.34</td></tr><tr><td>Benzolylanthracene</td><td>0.03</td><td>0.002</td><td>38.57</td><td>1.93</td><td>38.11</td><td>1.91</td></tr><tr><td>Chrysene</td><td>0.04</td><td>0.002</td><td>50.13</td><td>2.51</td><td>49.61</td><td>2.48</td></tr><tr><td>Cyclopentid,culysyner</td><td>0.02</td><td>0.001</td><td>48.84</td><td>2.44</td><td>60.04</td><td>3.00</td></tr><tr><td>S-Methylchrysene</td><td>0.04</td><td>0.002</td><td>ND</td><td>ND</td><td>2.48</td><td>0.12</td></tr><tr><td>Benzo[p]Iluonarthene</td><td>0.04</td><td>0.002</td><td>11.44</td><td>0.57</td><td>5.08</td><td>0.25</td></tr><tr><td>Benzol[Illicuranthene</td><td>0.05</td><td>0.003</td><td>12.41</td><td>0.62</td><td>5.07</td><td>0.25</td></tr><tr><td>Benzo[[aceanthrylene]</td><td>0.09</td><td>0.005</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>Benzoliglyreene</td><td>0.04</td><td>0.002</td><td>5.01</td><td>0.25</td><td>3.03</td><td>0.15</td></tr><tr><td>Indeno(1,2,1-cultypnee</td><td>0.02</td><td>0.001</td><td>5.46</td><td>0.27</td><td>1.54</td><td>0.08</td></tr><tr><td>Dibenodju/lipinthe cere</td><td>0.07</td><td>0.004</td><td>0.83</td><td>0.04</td><td>1.48</td><td>0.07</td></tr><tr><td>Dibenzolip/lyprene</td><td>0.05</td><td>0.003</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td></tr><tr><td>Dibenzolyadyprene</td><td>0.04</td><td>0.002</td><td>0.80</td><td>0.04</td><td>0.28</td><td>0.01</td></tr><tr><td>Dibenzolyuloyene</td><td>0.06</td><td>0.003</td><td>1.33</td><td>0.07</td><td>ND</td><td>ND</td></tr><tr><td>Dibenzolya/hyperene</td><td>0.07</td><td>0.004</td><td>2.99</td><td>0.15</td><td>ND</td><td>ND</td></tr></tbody>\n    </table>\n    </body>\n    </html>", "PMC6022086_007_00.png": "<html>\n    <head>\n    <meta charset=\"UTF-8\">\n    <style>\n    table, th, td {\n      border: 1px solid black;\n      font-size: 10px;\n    }\n    </style>\n    </head>\n    <body>\n    <table frame=\"hsides\" rules=\"groups\" width=\"100%\">\n    <thead><tr><td><b>Method</b></td><td><b>Data Type</b></td><td><b>Mean (m)</b></td><td><b>RMSE (m)</b></td><td><b>P90% (m)</b></td><td><b>PGSD (%)</b></td></tr></thead><tbody><tr><td rowspan=\"2\">Improved FCM</td><td>Gaofen-3</td><td>5.77</td><td>5.89</td><td>10.07</td><td>94.37</td></tr><tr><td>Sentinel-1</td><td>6.30</td><td>5.83</td><td>14.03</td><td>80.00</td></tr><tr><td rowspan=\"2\">Original FCM</td><td>Gaofen-3</td><td>6.97</td><td>7.66</td><td>13.87</td><td>90.70</td></tr><tr><td>Sentinel-1</td><td>8.53</td><td>4.81</td><td>13.14</td><td>90.00</td></tr></tbody>\n    </table>\n    </body>\n    </html>"}